Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970031/S076

Freestyle Bioprosthesis

Medtronic, Inc. · Decision date Nov 10, 2025

FDA DECISIONP970031/S076

What did the FDA approve?

FDA records P970031/S076 as a supplement to PMA P970031, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 10, 2025.

FDA approval order statement

Approval for implementation of updates to the product labels and IFUs, and the implementation of a new temperature indicator on the secondary package shelf cartons for the Mosaic, Hancock II, Avalus, and Freestyle bioprostheses
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Nov 10, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P970031/S076
Regulatory pathway
PMA supplement
Product code
LWR
Decision code
APPR
Decision date
Nov 10, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: heart-valve, non-allograft tissue.

Product code
LWR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P970031/S076 received

    Application receipt date recorded by FDA.

  2. P970031/S077 · Related supplement

    Freestyle Bioprosthesis, Models 995, 995CS, 995MS

  3. P970031/S076 · FDA decision

    Real-Time Process

  4. P970031/S078 · Related supplement

    Freestyle Bioprosthesis

Timeline entries are records held by MedtechLedger for P970031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970031

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 23, 2025FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA

Explore the linked device profile

Other records with product code LWR

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
1851 E. Deere Ave., Santa Ana, CA, 92705

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records